MA33053B1 - Inhibiteurs de la poly(adp-ribose) polymerase (parp) - Google Patents

Inhibiteurs de la poly(adp-ribose) polymerase (parp)

Info

Publication number
MA33053B1
MA33053B1 MA34106A MA34106A MA33053B1 MA 33053 B1 MA33053 B1 MA 33053B1 MA 34106 A MA34106 A MA 34106A MA 34106 A MA34106 A MA 34106A MA 33053 B1 MA33053 B1 MA 33053B1
Authority
MA
Morocco
Prior art keywords
parp
compounds
adp
ribose
polymerase
Prior art date
Application number
MA34106A
Other languages
Arabic (ar)
English (en)
Inventor
Anthony R Gangloff
Andrew John Jennings
Benjamin Jones
Andre A Kiryanov
Original Assignee
Tadeka Pharmaceutical Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42271897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33053(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tadeka Pharmaceutical Company Ltd filed Critical Tadeka Pharmaceutical Company Ltd
Publication of MA33053B1 publication Critical patent/MA33053B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I) SUIVANTE DANS LAQUELLE R1, R2, R3, R4, R5, R6, R7, X ET T SONT TELS QUE DÉFINIS DANS LE MÉMOIRE DESCRIPTIF. L'INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES, DES NÉCESSAIRES ET DES ARTICLES MANUFACTURÉS IMPLIQUANT LES COMPOSÉS, LES PROCÉDÉS ET LES INTERMÉDIAIRES UTILISABLES POUR LA FABRICATION DESDITS COMPOSÉS, AINSI QUE DES PROCÉDÉS D'UTILISATION DESDITS COMPOSÉS EN VUE DU TRAITEMENT DE MALADIES, D'AFFECTIONS ET DE TROUBLES ASSOCIÉS À L'ACTIVITÉ DE LA PARP.
MA34106A 2009-01-23 2010-01-21 Inhibiteurs de la poly(adp-ribose) polymerase (parp) MA33053B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14674009P 2009-01-23 2009-01-23
US22887909P 2009-07-27 2009-07-27
PCT/US2010/021669 WO2010085570A1 (fr) 2009-01-23 2010-01-21 Inhibiteurs de la poly(adp-ribose)polymérase (parp)

Publications (1)

Publication Number Publication Date
MA33053B1 true MA33053B1 (fr) 2012-02-01

Family

ID=42271897

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34106A MA33053B1 (fr) 2009-01-23 2010-01-21 Inhibiteurs de la poly(adp-ribose) polymerase (parp)

Country Status (23)

Country Link
US (5) US7928105B2 (fr)
EP (1) EP2389379A1 (fr)
JP (1) JP5567599B2 (fr)
KR (1) KR101779137B1 (fr)
CN (1) CN102341394B (fr)
AU (1) AU2010206744B2 (fr)
BR (1) BRPI1007358A2 (fr)
CA (1) CA2750106A1 (fr)
CL (1) CL2011001754A1 (fr)
CO (1) CO6410305A2 (fr)
CR (1) CR20110452A (fr)
DO (1) DOP2011000237A (fr)
EA (1) EA020301B1 (fr)
EC (1) ECSP11011284A (fr)
IL (1) IL213993A (fr)
MA (1) MA33053B1 (fr)
MX (1) MX2011007741A (fr)
MY (1) MY152386A (fr)
NZ (1) NZ594322A (fr)
PE (1) PE20120418A1 (fr)
SG (1) SG172958A1 (fr)
TN (1) TN2011000339A1 (fr)
WO (1) WO2010085570A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172958A1 (en) 2009-01-23 2011-08-29 Takeda Pharmaceutical Poly (adp-ribose) polymerase (parp) inhibitors
WO2011014681A1 (fr) 2009-07-30 2011-02-03 Takeda Pharmaceutical Company Limited Inhibiteurs de la poly (adp-ribose) polymérase (parp)
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
WO2011143660A2 (fr) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions et méthodes de traitement de la leucémie
KR101857599B1 (ko) 2010-05-14 2018-05-14 다나-파버 캔서 인스티튜트 인크. 종양형성, 염증성 질환 및 다른 장애를 치료하기 위한 조성물 및 방법
FI3461825T3 (fi) 2011-09-30 2023-08-17 C&C Res Lab Uusia heterosyklisiä johdannaisia ja niiden käyttöjä
MX367614B (es) 2012-01-20 2019-08-28 Del Mar Pharmaceuticals Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma.
CN104995190A (zh) * 2012-12-20 2015-10-21 拜耳医药股份有限公司 Bet蛋白抑制剂二氢喹喔啉酮
CN103923088B (zh) * 2013-01-11 2016-09-07 上海汇伦生命科技有限公司 2,5-二氮杂双环[2.2.1]庚烷类化合物和制备方法、其药用组合物及其在医药上的应用
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
WO2015004075A1 (fr) * 2013-07-09 2015-01-15 Bayer Pharma Aktiengesellschaft Dihydroquinoxalinones et dihydropyridopyrazinones inhibitrices de protéine bet modifiées
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
US9695172B2 (en) 2014-01-31 2017-07-04 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
JP2017504653A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアミノピリミジンベンゼンスルホン誘導体およびその使用
US10925881B2 (en) 2014-02-28 2021-02-23 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
KR102310128B1 (ko) 2014-07-14 2021-10-06 주식회사 포스코 트리아진-피페라진 골격을 갖는 알파-헬릭스 유사체 및 이의 제조방법
WO2016022902A1 (fr) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dérivés de diazépane et leurs utilisations
CA2955077A1 (fr) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Derives de dihydropteridinone et leurs utilisations
AU2015339511B2 (en) 2014-10-27 2020-05-14 Tensha Therapeutics, Inc. Bromodomain inhibitors
EP3307728A4 (fr) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
RU2750164C2 (ru) 2015-09-11 2021-06-22 Дана-Фарбер Кэнсер Инститьют, Инк. Цианотиенотриазолодиазепины и пути их применения
WO2017091673A2 (fr) 2015-11-25 2017-06-01 Dana-Farber Cancer Institute, Inc. Inhibiteurs de bromodomaines bivalents et leurs utilisations
EP3440052B1 (fr) 2016-04-06 2023-10-25 University Of Oulu Composés pour utilisation dans le traitement du cancer
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
EP3267192B1 (fr) * 2016-07-07 2020-08-19 Alpha M.O.S. Chromatographe en phase gazeuse comprenant des capteurs a oxyde metallique
CN106883232B (zh) * 2017-03-31 2019-01-22 苏州康润医药有限公司 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用
CA3145644A1 (fr) * 2019-07-19 2021-01-28 Astrazeneca Ab Inhibiteurs de parp1
CN111097386B (zh) * 2019-12-26 2022-01-11 江苏大学 一种二维层状水稳定染料吸附剂及制备方法
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
CA3216373A1 (fr) 2021-04-19 2022-10-27 Lynnie TRZOSS Inhibiteurs de parp1 et leurs utilisations
WO2022222921A1 (fr) * 2021-04-22 2022-10-27 微境生物医药科技(上海)有限公司 Inhibiteur de parp contenant une structure de pipérazine, son procédé de préparation et son utilisation pharmaceutique
CN117083274A (zh) * 2021-04-23 2023-11-17 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
WO2022222995A1 (fr) * 2021-04-23 2022-10-27 南京明德新药研发有限公司 Composé picolinamide
WO2022222966A1 (fr) * 2021-04-23 2022-10-27 成都百裕制药股份有限公司 Inhibiteur sélectif de parp1 et son application
AU2022334408A1 (en) * 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
WO2023046034A1 (fr) * 2021-09-22 2023-03-30 明慧医药（杭州）有限公司 Composé hétérocyclique contenant de l'azote, son procédé de préparation, intermédiaire de celui-ci et application de celui-ci
WO2023046158A1 (fr) * 2021-09-26 2023-03-30 张文燕 Composé d'azaquinolinone et son utilisation médicale
WO2023046149A1 (fr) * 2021-09-26 2023-03-30 张文燕 Composé quinoxaline et son utilisation médicinale
WO2023051807A1 (fr) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 Inhibiteur de parp dérivé bicyclique et son utilisation
WO2023051812A1 (fr) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 Dérivé hétérocyclique contenant de l'azote à utiliser en tant qu'inhibiteur de parp et son utilisation
WO2023051716A1 (fr) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 Inhibiteur de parp dérivé d'hétéroaryle et son utilisation
TW202322807A (zh) 2021-10-01 2023-06-16 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
WO2023061406A1 (fr) * 2021-10-12 2023-04-20 微境生物医药科技(上海)有限公司 Inhibiteur de parp contenant une structure tricyclique condensée, son procédé de préparation et son utilisation médicale
WO2023096915A1 (fr) * 2021-11-24 2023-06-01 Slap Pharmaceuticals Llc Composés multicycliques
WO2023109521A1 (fr) * 2021-12-17 2023-06-22 凯复(苏州)生物医药有限公司 Inhibiteur de parp, composition pharmaceutique le comprenant et son utilisation
WO2023134647A1 (fr) * 2022-01-13 2023-07-20 优领医药科技(香港)有限公司 Dérivé contenant un cycle pipérazino, sel pharmaceutiquement acceptable de celui-ci, son procédé de préparation et son utilisation
US11939329B2 (en) 2022-01-21 2024-03-26 Xinthera, Inc. PARP1 inhibitors and uses thereof
WO2023169226A1 (fr) * 2022-03-11 2023-09-14 Impact Therapeutics (Shanghai), Inc Composés tricycliques substitués utilisés en tant qu'inhibiteurs de parp et leur utilisation
TW202400596A (zh) 2022-04-28 2024-01-01 美商辛瑟拉股份有限公司 三環parp1抑制劑及其用途
WO2023207284A1 (fr) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Dérivés de pipérazine utilisés comme inhibiteurs de parp1

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138564A (en) * 1977-08-03 1979-02-06 American Home Products Corporation Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof
US4446323A (en) 1983-05-23 1984-05-01 American Home Products Corporation Tetra- and hexa-hydropyrrolo(1,2-a)quinoxaline and azaquinoxaline derivatives
US5055465A (en) 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
US5166344A (en) 1989-05-31 1992-11-24 Berlex Laboratories, Inc. Process for the preparation of imidazoquinoxalinones
DE4228095A1 (de) 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
TW274550B (fr) 1992-09-26 1996-04-21 Hoechst Ag
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6121278A (en) 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
EP1339402B1 (fr) 2000-12-01 2010-08-25 Eisai Inc. Derives d'azaphenanthridone et leur utilisation comme inhibiteurs de parp
GB0206219D0 (en) * 2002-03-15 2002-05-01 Ferring Bv Non-Peptide GnRH antagonists
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
UA91007C2 (ru) 2003-12-10 2010-06-25 Янссен Фармацевтика Н.В. Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразы
KR20070027584A (ko) 2004-06-17 2007-03-09 와이어쓰 고나도트로핀 방출 호르몬 수용체 길항제
US7947682B2 (en) 2004-12-29 2011-05-24 University Of Southern California Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents
US20090093489A1 (en) 2004-12-29 2009-04-09 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function
EP1816913A4 (fr) 2004-11-01 2010-02-24 Univ Southern California Nouveaux composes utiles pour le traitement du cancer et des troubles associes a la fonction d'angiogenese
EP1845996A4 (fr) * 2005-01-03 2009-04-29 Univ Michigan Compositions et procedes concernant de nouveaux composes et leurs cibles
WO2006125179A1 (fr) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Composes tricycliques: utilisation comme agents therapeutiques
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
GB0615809D0 (en) 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
ES2566774T3 (es) 2006-12-13 2016-04-15 Aska Pharmaceutical Co., Ltd. Derivado de quinoxalina
CA2672591A1 (fr) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Agent therapeutique de l'uropathie
HUE027641T2 (en) 2006-12-28 2016-11-28 Abbvie Inc Poly (ADP-ribose) polymerase inhibitors
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
CN101302214B (zh) * 2007-05-11 2012-06-20 江苏国华投资有限公司 芳烷基哌啶(嗪)衍生物及在治疗精神神经疾病中的应用
WO2009086303A2 (fr) 2007-12-21 2009-07-09 University Of Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
SG172958A1 (en) 2009-01-23 2011-08-29 Takeda Pharmaceutical Poly (adp-ribose) polymerase (parp) inhibitors
US8551996B2 (en) 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment

Also Published As

Publication number Publication date
CL2011001754A1 (es) 2012-01-20
US8124606B2 (en) 2012-02-28
CN102341394B (zh) 2015-04-15
EP2389379A1 (fr) 2011-11-30
US8822470B2 (en) 2014-09-02
MY152386A (en) 2014-09-15
BRPI1007358A2 (pt) 2018-03-06
US20130274239A1 (en) 2013-10-17
US20110158989A1 (en) 2011-06-30
NZ594322A (en) 2013-01-25
CA2750106A1 (fr) 2010-07-29
CO6410305A2 (es) 2012-03-30
CR20110452A (es) 2012-02-28
AU2010206744A1 (en) 2011-08-04
ECSP11011284A (es) 2011-10-31
WO2010085570A1 (fr) 2010-07-29
US7928105B2 (en) 2011-04-19
JP5567599B2 (ja) 2014-08-06
US20100190763A1 (en) 2010-07-29
US20120122835A1 (en) 2012-05-17
KR101779137B1 (ko) 2017-09-18
MX2011007741A (es) 2011-09-06
IL213993A0 (en) 2011-08-31
KR20110107396A (ko) 2011-09-30
CN102341394A (zh) 2012-02-01
EA201170963A1 (ru) 2012-03-30
PE20120418A1 (es) 2012-05-04
SG172958A1 (en) 2011-08-29
AU2010206744B2 (en) 2015-08-20
DOP2011000237A (es) 2011-09-15
EA020301B1 (ru) 2014-10-30
US9187497B2 (en) 2015-11-17
IL213993A (en) 2017-03-30
US20150031652A1 (en) 2015-01-29
TN2011000339A1 (en) 2013-03-27
US8450323B2 (en) 2013-05-28
JP2012515786A (ja) 2012-07-12

Similar Documents

Publication Publication Date Title
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA35246B1 (fr) 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2
MA35193B1 (fr) Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2
MA35191B1 (fr) Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
EA200802054A1 (ru) Ингибиторы фермента
TN2012000192A1 (fr) N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
MA35576B1 (fr) Nouveaux composés
MA31373B1 (fr) Composes amino-heterocycliques
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA34797B1 (fr) Hétéroaryles et leurs utilisations
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA44948A1 (fr) Inhibiteurs de bace 1
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
MA32798B1 (fr) Acides naphtylacétiques
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MA37763B1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1